Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Tect Patch Detection Accuracy and Latency Trial
NCT06372210Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aripiprazole in schizophrenia, major depressive disorder (MDD) and bipolar I disorder (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Positive Detection Accuracy at Day 1, Patch Detection Latency Period at Day 1 and 2 more. Started Jun 2023; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniamajor depressive disorder (MDD)bipolar I disorder
Beyond the preview
Go deeper on NCT06372210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372210.